Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBITDA: 2010-2025

Historic EBITDA for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' EBITDA rose 20.21% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 52.37%. This contributed to the annual value of $163.9 million for FY2024, which is 129.61% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' EBITDA is $52.8 million, which was up 1.14% from $52.2 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBITDA peaked at $56.7 million during Q1 2025, and registered a low of -$30.8 million during Q3 2023.
  • For the 3-year period, Catalyst Pharmaceuticals' EBITDA averaged around $36.1 million, with its median value being $40.8 million (2024).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EBITDA crashed by 234.30% in 2023 and then soared by 242.63% in 2024.
  • Catalyst Pharmaceuticals' EBITDA (Quarterly) stood at $9.2 million in 2021, then surged by 176.05% to $25.5 million in 2022, then soared by 36.84% to $34.8 million in 2023, then surged by 60.72% to $56.0 million in 2024, then rose by 20.21% to $52.8 million in 2025.
  • Its EBITDA stands at $52.8 million for Q3 2025, versus $52.2 million for Q2 2025 and $56.7 million for Q1 2025.